NCT00237133

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

PREDICT TRIAL- Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 112 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)

Conditions

• Locally Advanced Breast Cancer

Interventions

Type	Name	Description
DRUG	Letrozole	1 tablet of Letrozole 2.5 mg orally adminnistered once a day

Timeline

• Start date: 2003-03-01
• Primary completion: 2009-01-01
• Completion: 2009-01-21
• First posted: 2005-10-12
• Last updated: 2017-02-24

Locations

11 sites across 1 country: Brazil